11C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial)

Table 1 Patients’ characteristics

	Primary tumor	NAC^a
No of patients in phase of study	15	5
Gender (Male/Female)	13/2	5
Age (years)	67 (55–79)	65 (57–69)
ASA-score	2 (1–3)	2
BMI (kg/m²)	27 (23–31)	26 (23–30)
Treatment modality
TUR-BT and surveillance	5	N/A
TUR-BT and BCG	7	N/A
TUR-BT, NAC, RC and EPLND	2	5
TUR-BT, BCG and RC^b	1	N/A

Mean values and range are given, when feasible. ASA-score The American Society of Anesthesiologists physical status grading system; BMI body mass index, TUR-BT Transurethral resection of bladder tumor, BCG Bacillus-Calmette-Guerin bladder instillations, RC radical cystectomy, EPLND extended pelvic lymph node dissection, N/A not applicable
^a2 patients participated in both phases of the study
^bRC due to disease progression

ISSN: 1470-7330